Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02846623
Title Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

CLL/SLL

chronic lymphocytic leukemia

Therapies

Atezolizumab + Obinutuzumab + Venetoclax

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.